Nasonex nasal spray 50 mcg/dose, 18 g (140 doses) — Made in Belgium — Free Delivery

Spray nasal "Nasonex®" is used for the following indications:

One spray dose contains (active ingredient) mometasone furoate monohydrate (micronized) in an amount equivalent to 50 μg of mometasone furoate (anhydrous).

Excipients: dispersed cellulose (microcrystalline cellulose and sodium carboxymethyl cellulose); glycerol; citric acid, monohydrate; sodium citrate, dihydrate; polysorbate-80; benzalkonium chloride solution; purified water.

Hypersensitivity to the active substance or to any inactive component of the drug.

Before using a new vial of the drug, it should be calibrated. Calibration is carried out by approximately 10 pushes of the dosing device, while a stereotyped delivery of the drug is established, in which approximately 100 mg of a suspension containing 50 μg of mometasone (one dose) is emitted with each press. If the nasal spray is not used for 14 days or longer, a second “spray” with 2 pressings must be observed before subsequent use until a complete delivery is observed. Do not pierce the tip before use.

Shake the bottle vigorously before each use.

If the nozzle is clogged, you need to remove the plastic cap by gently pressing on the white ring, easily remove the nozzle and rinse it with warm running water, dry it and reinstall it. Do not try to clean the nozzle with a needle or other sharp object, as doing so will damage the dispenser.

Regular cleaning of the nozzle is very important.

Before each use, thoroughly cleanse the nose of mucus.

Treatment of seasonal or year-round allergic rhinitis: for adults (including the elderly) and children over 12 years of age, the recommended prophylactic and therapeutic dose of the drug is 2 injections (50 μg each) into each nostril 1 time per day (total daily dose - 200 μg). After reaching the therapeutic effect for maintenance therapy, it is advisable to reduce the dose to one injection into each nostril 1 time per day (total daily dose - 100 mcg). If the weakening of the symptoms of the disease cannot be achieved by using the drug in the recommended therapeutic dose, the daily dose can be increased to the maximum: 4 injections into each nostril 1 time per day (total daily dose - 400 mcg). After the symptoms of the disease have subsided, a dose reduction is recommended. The drug demonstrated a clinically significant onset of action within 12 hours after the first use in some patients with seasonal allergic rhinitis. However, the full benefit of the treatment cannot be obtained in the first 48 hours, so the patient must continue to use it regularly to achieve the full therapeutic effect. For children 2-11 years old, the recommended therapeutic dose is one injection (50 mcg) into each nostril once a day (total daily dose is 100 mcg).

Adjunctive treatment of acute sinusitis. For adults (including the elderly) and children over 12 years of age, the recommended therapeutic dose is 2 injections (50 mcg each) into each nostril 2 times a day (total daily dose - 400 mcg). If the weakening of the symptoms of the disease cannot be achieved by using the drug in the recommended therapeutic dose, the daily dose can be increased to 4 injections into each nostril 2 times a day (total daily dose - 800 mcg). After the symptoms of the disease have subsided, a dose reduction is recommended.

Acute rhinosinusitis. For adults and children over 12 years of age, the recommended therapeutic dose is 2 injections (50 mcg) into each nostril 2 times a day (total daily dose is 400 mcg).

Nasal polyps. For patients over 18 years of age (including the elderly), the recommended dose is 2 injections (50 mcg) into each nostril 2 times a day (total daily dose is 400 mcg). After achieving the clinical effect, it is recommended to reduce the dose to 2 injections into each nostril once a day (total daily dose - 200 mcg).

Corticosteroid preparations should not be used by pregnant or breastfeeding women unless absolutely necessary.